Journal
LIVER INTERNATIONAL
Volume 43, Issue 6, Pages 1157-1169Publisher
WILEY
DOI: 10.1111/liv.15387
Keywords
HBV RNA; hepatitis B therapy; interferon alpha-2; nucleosides; prognosis; quantitative HBsAg
Categories
Ask authors/readers for more resources
HDV uses the HBV surface antigen to enter hepatocytes and is associated with accelerated fibrosis progression and increased risk of hepatocellular carcinoma. Current HBV antiviral agents have poor activity against HDV, therefore the search for drugs that can cure both HBV and HDV is needed.
HDV is a defective virus that uses the HBV surface antigen to enter hepatocytes. It is associated with an accelerated course of liver fibrosis progression and an increased risk of hepatocellular carcinoma. Negative HDV RNA 24 weeks after the end of therapy has been proposed as an endpoint but late relapses make this endpoint suboptimal, hence HBsAg loss appears to be more appropriate. Current HBV antiviral agents have poor activity against HDV hence the search for improved therapy. Drugs only active against HDV, such as lonafarnib, have shown efficacy in combination with nucleoside analogues and peginterferon, but do not lead to HBsAg loss. HBsAg loss sustained 24 weeks after the end of therapy with negative HBV DNA is termed functional cure. Agents that are being investigated for functional cure include those that inhibit replication such as entry inhibitors, polymerase inhibitors and capsid assembly modulators but seldom lead to functional cure. Agents that reduce HBV antigen load such as RNA interference and inhibitors of HBsAg secretion are promising. Immunomodulators on their own seldom achieve functional cure, hence these agents in combination to assess the optimal combination are being investigated. Consequently, agents leading to functional cure of HBV are ideal for both HBV and HDV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available